Skip to main content

Table 4 Changes in T-SPOT spot counts and prognosis in NSCLC patients undergoing ICIs treatment

From: Impact of immune checkpoint inhibitors (ICIs) therapy on interferon-γ release assay (IGRA) and diagnostic value in non-small cell lung cancer (NSCLC) patients

T-SPOT Counts

Increase

n = 4

No change

n = 12

Decrease

n = 16

P value

Prognosis, n(%)

PD

2(50.0)

8(66.7)

10(62.5)

0.527

DCR

2(50.0)

4(33.3)

6(37.5)

Dead

0(0.0)

3(25.0)

4(25.0)

0.837

Survival

4(100.0)

9(75.0)

12(75.0)

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us